Jason A. Okazaki - Mar 27, 2024 Form 4 Insider Report for ASSEMBLY BIOSCIENCES, INC. (ASMB)

Role: CEO and President, Director
Signature: /s/ John O. Gunderson, as Attorney-in-Fact
Stock symbol: ASMB
Transactions as of: Mar 27, 2024
Transactions value $: -$5,045
Form type: 4
Date filed: 3/29/2024, 04:05 PM
Previous filing: Oct 4, 2023
Next filing: Apr 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ASMB	Common Stock	Sale	-$5.05K	-392	-2.69%	$12.87	14.2K	Mar 27, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
F2	Reflects equitable adjustment of the number of shares of common stock beneficially owned by the reporting person as a result of a 1-for-12 reverse stock split of the Issuer's common stock effected February 9, 2024, which is exempt from reporting pursuant to Rule 16a-9.

Content

The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

Reflects equitable adjustment of the number of shares of common stock beneficially owned by the reporting person as a result of a 1-for-12 reverse stock split of the Issuer's common stock effected February 9, 2024, which is exempt from reporting pursuant to Rule 16a-9.